A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 lesions. Dual imaging might help.

But an association with improved overall survival failed to reach statistical significance ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Risk factors like Gleason score, cancer stage, PSA levels, and genetic markers guide prostate cancer treatment decisions. Treatment options include active surveillance, surgery, radiation, hormone ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...

As reports surface that the UK’s national screening committee are set to reject proposals for any national prostate screening programme, experts warn that the decision, if followed through with, puts ...